NO20056153L - Preparat omfattende antiprogestiner og rene antiostrogener for profylakse og behandling av hormon-avhengige sykdommer - Google Patents

Preparat omfattende antiprogestiner og rene antiostrogener for profylakse og behandling av hormon-avhengige sykdommer

Info

Publication number
NO20056153L
NO20056153L NO20056153A NO20056153A NO20056153L NO 20056153 L NO20056153 L NO 20056153L NO 20056153 A NO20056153 A NO 20056153A NO 20056153 A NO20056153 A NO 20056153A NO 20056153 L NO20056153 L NO 20056153L
Authority
NO
Norway
Prior art keywords
hormone
treatment
pure
dependent diseases
antiostrogens
Prior art date
Application number
NO20056153A
Other languages
English (en)
Inventor
Martin Schneider
Ulrike Fuhrmann
Jens Hoffmann
Gerhard Siemeister
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33450989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20056153(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20056153L publication Critical patent/NO20056153L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår metoder og anvendelse for forebygging og behandling av hormonavhengige sykdommer, spesielt brystkreft hos pattedyr, med en kombinasjon av et anti-progestin, spesielt antiprogestinet 11 ?-(-4-acetyl-fenyl)-17?? -hydroksy-17a-( 1,1,2,2,2-pentafluor-etyl)-østra-4,9-dien-3-on eller et farmasøytisk akseptabelt derivat eller analog derav, og et rent antiøstrogen, spesielt en forbindelse med den generelle formel (I) slik den er definert i beskrivelsen, for eksempel 11 ? -fluor-17a-metyl-7a-{5-[metyl(8,8,9,9,9-penta-fluornonyl)amino]-pentyl}-østra-1,3,5(10)-trien-3,17?? -diol. Oppfinnelsen angår videre farmasøytiske sammensetninger som omfatter nevnte kombinasjon.
NO20056153A 2003-05-28 2005-12-23 Preparat omfattende antiprogestiner og rene antiostrogener for profylakse og behandling av hormon-avhengige sykdommer NO20056153L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/446,165 US20040242551A1 (en) 2003-05-28 2003-05-28 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
PCT/EP2004/005732 WO2004105768A1 (en) 2003-05-28 2004-05-27 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Publications (1)

Publication Number Publication Date
NO20056153L true NO20056153L (no) 2006-02-22

Family

ID=33450989

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056153A NO20056153L (no) 2003-05-28 2005-12-23 Preparat omfattende antiprogestiner og rene antiostrogener for profylakse og behandling av hormon-avhengige sykdommer

Country Status (18)

Country Link
US (3) US20040242551A1 (no)
EP (2) EP1628669A1 (no)
JP (1) JP2006528226A (no)
KR (1) KR20060005412A (no)
CN (1) CN1893955A (no)
AR (1) AR044450A1 (no)
AU (1) AU2004243500A1 (no)
BR (1) BRPI0410707A (no)
CA (1) CA2524750A1 (no)
CL (1) CL2004001317A1 (no)
EA (1) EA011506B1 (no)
MX (1) MXPA05012841A (no)
NO (1) NO20056153L (no)
PE (1) PE20050207A1 (no)
TW (1) TW200505936A (no)
UY (1) UY28334A1 (no)
WO (1) WO2004105768A1 (no)
ZA (1) ZA200510449B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
KR20060014071A (ko) * 2003-06-10 2006-02-14 교와 핫꼬 고교 가부시끼가이샤 티아디아졸린 유도체
CA2683809A1 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen
US20080261929A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
PT2983671T (pt) * 2013-04-11 2019-02-25 Bayer Pharma AG Forma farmacêutica de antagonista de recetor de progesterona
CN115505019B (zh) * 2022-11-07 2024-01-26 南宁师范大学 7-酰胺取代雌甾类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36654A (en) * 1970-04-24 1974-07-31 Ciba Geigy Ag 3-cyclopentyl ethers of 7alpha-methyl-3,16alpha,17(alpha and beta)-trihydroxy-delta 1,3,5(10)-estratriene,their manufacture and estrogenic pharmaceutical compositions containing them
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
EP0310542B1 (de) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
DE19622457A1 (de) * 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
PE20000129A1 (es) * 1997-12-23 2000-03-11 Schering Ag 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
DE19807791A1 (de) * 1998-02-19 1999-08-26 Schering Ag Kombinationspräparat aus Östrogen und Antiöstrogen
PL360157A1 (en) * 2000-10-18 2004-09-06 Schering Aktiengesellschaft Use of antiprogestins for the induction of apoptosis in a cell
IL154975A0 (en) * 2000-10-18 2003-10-31 Schering Ag Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Also Published As

Publication number Publication date
PE20050207A1 (es) 2005-04-28
AU2004243500A1 (en) 2004-12-09
KR20060005412A (ko) 2006-01-17
EA011506B1 (ru) 2009-04-28
AR044450A1 (es) 2005-09-14
EP1834644A3 (en) 2007-11-07
UY28334A1 (es) 2004-12-31
CL2004001317A1 (es) 2005-05-06
JP2006528226A (ja) 2006-12-14
WO2004105768A1 (en) 2004-12-09
CA2524750A1 (en) 2004-12-09
US20040242551A1 (en) 2004-12-02
WO2004105768A8 (en) 2006-04-06
TW200505936A (en) 2005-02-16
ZA200510449B (en) 2007-04-25
EP1628669A1 (en) 2006-03-01
MXPA05012841A (es) 2006-02-13
CN1893955A (zh) 2007-01-10
EP1834644A2 (en) 2007-09-19
US20070238714A1 (en) 2007-10-11
EA200501739A1 (ru) 2006-06-30
US20050014736A1 (en) 2005-01-20
BRPI0410707A (pt) 2006-06-13

Similar Documents

Publication Publication Date Title
NO20056153L (no) Preparat omfattende antiprogestiner og rene antiostrogener for profylakse og behandling av hormon-avhengige sykdommer
US8349820B2 (en) Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido
JP2019163318A5 (no)
IL216194A0 (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
TW200716137A (en) Tanaproget compositions containing ethinyl estradiol
RS50972B (sr) Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate
CY1104981T1 (el) Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων
ATE452641T1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
ZA201908404B (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
NO20072687L (no) Farmasoytisk prevensjonspreparat
EA200701389A1 (ru) Твёрдая пероральная лекарственная форма для контрацепции
DE60121980D1 (de) Verwendung von 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-on zur herstellung eines medikaments zur behandlung von brust-, eierstock-, endometrium-krebs, myelom und meningiom
RU2004116082A (ru) Применение (11бета, 17 бета)-11-(1,3-бензодиоксол-5-ил)-17-гидрокси-17-(1-пропинил) эстра-4,9-диен-3-она при лечении большого депрессивного расстройства
UA85190C2 (en) PROCESS FOR THE SYNTHESIS OF PURE D-(17α)-13-ETHYL-17-HYDROXY-18,19-DINORPREGN-4-ENE-20-YNE-3-ONE-3E- AND -3Z-OXIME ISOMERS AND THE MIXTURE OF ISOMERS, AND USE OF THOSE ISOMERS
YU30103A (sh) Upotreba antiprogestina za profilaksu i lečenje hormonski zavisnih bolesti
TW200733955A (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
UY29378A1 (es) Preparación farmaceutica para la anticoncepción oral
TH76790A (th) สารผสมซึ่งประกอบรวมด้วยโปรเจสเทอโรน-รีเซพเตอร์ แอนทาโกนิสท์ และแอนติเอสโทรเจ็นบริสุทธิ์ สำหรับการป้องกันโรค และการบำบัดโรคที่ต้องพึ่งพาฮอร์โมน
MEP38208A (en) COMPOSITION CONTAINING AN ANDROGENOUS 11beta-HALOGEN STEROID AND A PROGESTATIONAL HORMONE, AND MALE CONTRACEPTIVE BASED ON SAID COMPOSITION

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application